The
State Key Laboratory of Molecular Oncology was established on
November 1988 and is located at the Chinese Academy of Medical
Sciences, Cancer Institute. Currently, there are 30 research staffs;
including 9 senior investigators in the Key Lab. Dr. Qimin Zhan
is the Director of the Key laboratory and the Chairman of Scientific
Committee.
The
mainstream research of the laboratory has been focused on several
important issues: (1). To investigate the impact of genetic factors
on tumorigenesis and explore the interactions between genetic
factors and environmental stimuli. (2). To determine the roles
of cell cycle control, apoptosis in the maintenance of genomic
fidelity, and seek for the molecular mechanism(s) by which genomic
instability contributes to cell transformation and carcinogenesis.
(3). To carry out studies on genetic/molecular epidemiology, cytogenetics
and molecular genetics in the high incidence areas for esophageal
or liver cancers. The long-term goal of the State Key Laboratory
of Molecular Oncology is to unravel the mechanism of carcinogenesis,
particularly in esophageal cancer, liver cancer and lung cancer.
The
laboratory consists of multiple research groups, including the
Section of Molecular Mechanism of Carcinogenesis, Gene Therapy,
Early Prevention and Molecular Regulation of Esophageal Cancer,
Mechanism of Liver Cancer, Early Diagnosis and Immuno-therapy
of Liver Cancer and the Section of Cancer Genome. Over the past
ten years, the Key Lab has made significant progress in understanding
molecular alterations of esophageal carcinogenesis, including
chromosomal instability and disrupted differentiation and apoptotic
pathways. In addition, the Lab has made first demonstration that
both HBV and Alpha-toxin are closely associated with liver carcinogenesis.
At
the present time, the Key lab is well funded by a variety of funding, such as the State Key Basic Research Grant of China (973), the Chinese High-Tech R&D Program Grant (863), the Program Research Grants from the National Natural Science Foundation and the Chinese National 10th-5-year Medical Strategic Science and Technology Plan. This State Key Lab is currently running a strong graduate program. Since 1988, more than 109 graduate students and twenty five postdoctoral fellows have been well trained in this laboratory. Within the past five years, the State Key Laboratory of Molecular Oncology has been productive and totally published more than hundreds papers, some of which are in prestigious journals in the field of cancer biology. In addition, 10 patents have been approved by both the national and international patent agencies.
There
are much international collaboration between the State Key Laboratory
of Molecular Oncology and some world-leading medical institutions,
including National Cancer Institute of NIH, University of Pittsburgh
School of Medicine Cancer Institute, and M.D. Anderson Cancer
Center in the United States, the British ICRF and the World Health
Organization
State
Key Laboratory of Molecular Oncology
Cancer Institute，Cancer Hospital
Peking Union Medical College
Chinese Academy of Medical Sciences
P.O.Box 2258
Beijing 100021
P.R.China
Te l: 86-10- 67762694, 86-10- 87714054
FAX: 86-10- 6 |
